Index

This index uses letter-by-letter alphabetization, ignoring spaces and hyphens. Page numbers in **bold** indicate tables; page numbers in *italics* indicate figures.

---

**A4GALT1** gene 173–174

**AA4B Standards**

adverse reactions after blood donation 43–45
anemia and RBC transfusion 123
apheresis 377
bacterial contamination of blood components 611, 614, 617
blood administration 23–24, 27
donor recruitment and screening 31, 32, 35–36
parasite transmission during transfusion 599, 605
perioperative transfusion needs 556–558
platelets 227
safety and availability of blood/blood products 69, 74, 76
testing for pathogens in donors 629–630
tissue banking 477
**AA4M see Association for the Advancement of Medical Instrumentation**

**AA4PC see artificial antigen-presenting cells**

**AA4TB see American Association of Tissue Banks**

**AAV see adeno-associated viral vector**

**AC see America’s Blood Centers**

**AC/ERA see America’s Blood Centers/European Blood Alliance**

abciximab 255, 353

**ABH antibodies** 160, 160, 165

**ABO blood group system** 159–165

**ABH antibodies** 160, 160, 165

**ABO gene** 161–162, 161

antigens on platelet surface 215–216, 216, 220
autoimmune hemolytic anemias 148–149
biological roles 164–165

**Bombay and para-Bombay** 161

cancer 574–577
chemistry and biosynthesis 159–160, 160
compatibility testing 198–200, 202–204
donor recruitment and screening 38
hemolytic disease of the fetus and newborn 528–530
hemolytic transfusion reactions 644–651
H gene 162–163, 163
malaria, blood groups, and hemoglobinopathy 127–128
molecular biology 161–163
plasma 288
platelet administration 238
platelet storage 232–233
serology 160–161, 160

tissue banking 476
transfusion and transplantation 164
weak ABO subtypes 160–161
absent iron stores (AIS) 52–53
absolute neutrophil count (ANC) 267
ACD see acid–citrate–dextrose
ACE see angiotensin-converting enzyme
acelular skin substitutes 489
actin 212
adeno-associated viral vector 454
adequate activated factor VII 345–346, 346
uremia 353
vitamin K deficiency 348, 354–357
acquired factor X deficiency 352
acquired hemophilia 350–351, 350
acquired platelet disorders 236–237
acquired von Willebrand syndrome (AvWS) 351–352, 413
ACS see acute coronary syndrome
actin 212
activated partial thromboplastin time (aPTT) 292–294, 293, 299–300
perioperative transfusion needs 552–553, 557
plasma transfusions for infants and children 546
activated prothrombin complex concentrate (aPCC) 312
acute chest syndrome 132, 408
acute coronary syndrome (ACS) 120
acute hemolytic transfusion reactions (AHTR) 642, 647, 650
acute hepatic failure 405–406
acute lymphoblastic leukemia (ALL) 218–219
acute lymphocytic leukemia (ALL) 445, 450
acute multiorgan failure syndrome 408
acute myelogenous leukemia (AML) 217
acute normovolemic hemodilution (ANH) 19–20, 575
acute phase reaction 288
acute respiratory distress syndrome (ARDS) 27
Acute Trauma Life Support (ATLS) 562–563
additive solutions (AS) 294
platelets 232–233, 233
red blood cells 103–106, 105, 538–539, 539
adenosine diphosphate (ADP) 98–101, 108
adenosine triphosphate (ATP) 98–101, 108
adenovirus 480
adjuncts in transfusion therapy 571–573
adoptive immunotherapy 479–487
dendritic cell immunotherapy 482–483
mesenchymal stromal cell immunotherapy 485–487, 486
adaptive immunotherapy (Continued)

natural killer cell immunotherapy 483–485
T-cell immunotherapy 479–482

ADP see adenosine diphosphate

adverse reactions 248–249

acute reactions 44–49
allergic reactions 652, 657–658
anaphylactic/anaphylactoid reactions 652, 658–660
apheresis 385–386
automated collection of blood components 43–44, 44, 47–48
blood donation 43–49
cancer 578–579
citrated reactions 48
complications of massive and rapid transfusion 660–663
donation frequency and multiple component collection 48–49
donor vigilance and hemovigilance 61, 64–67
febrile, nonhemolytic transfusion reactions 652–657
granulocyte collection 49
hematopoietic growth factors 421, 424, 426–427
hematopoietic progenitor cells 579
hemolytic reactions 364–365
immediate reactions 363–364
immediate symptoms and delayed complications 44–49
immunoglobulin products 363–365
iron deficiency 53–54
nerve injury 47
phlebotomy-related complications 46–47
platelet transfusions for infants and children 545–546
preventing syncopal reactions at blood drives 45–46, 45
procedure-related complications 48–49
risk factors 44–45, 45
special transfusion settings 664–666
thromboembolic events 364
toxic reactions from blood manufacture or processing 663–664
transfusion monitoring 141
whole blood collection 43–44, 44, 47–48

(Keys) Aedes spp. 593–594
AF see atrial fibrillation
alfuradon 342
Agency for Healthcare Research and Quality (AHRQ) 697
agglutination
autoimmune hemolytic anemias 148–149
plasma 310–311
red cell immunology 197
AHF see antigemophilic factor
AHRQ see Agency for Healthcare Research and Quality
AHTR see acute hemolytic transfusion reactions
aHUS see atypical hemolytic uremic syndrome
AIHA see autoimmune hemolytic anemia
AIS see absent iron stores
alnine transferase (ALT) 584–585
albumin 286–287, 305–306, 306
ALCL see anaplastic large-cell lymphoma
aliquoting 26

alkylizing spondylitis 462–463
ALL see acute lymphoblastic leukemia; acute lymphocytic leukemia
allele-specific polymerase chain reaction 248–249
allergic reactions 657–658
aplasia 386
competition and definitions 652, 657, 665
diagnosis 657
etiology 657
prevention 658
treatment 657–658
alloantibodies
autoimmune hemolytic anemias 145, 148–149
hemolytic transfusion reactions 644–645
therapeutic plasma exchange 399–400
transfusion monitoring 138–140
alloantigens 259
alloimmune blood transfusion (ABT) 695–710
beneficial clinical TRIM effects 695–697
concepts and definitions 695, 696
deleterious clinical TRIMM effects 697–703
enhanced survival of renal allografts 695–697
increased risk of postoperative bacterial infection 698–699, 699, 705, 705–706
increased risk of short-term posttransfusion mortality 699–700, 700
increase recurrence of resected malignancies 697–698, 708, 708
length of RBC storage 702–703
mechanisms of TRIM effects in cardiac surgery and trauma 700–701, 701
mediation of TRIM effects by alloimmune mononuclear cells 705–708
mediation of TRIM effects by WBC-derived soluble mediators 704–705
microchimerism 707–708
reduced risk of recurrence of Crohn’s disease 697
reduced risk of RSAs 697
soluble molecules circulating in allogeneic plasma 703–704
studies before-and-after WBC reduction 701–702
transfusion-related immunomodulation 695–710
alloimmune hematopoietic stem cell transplantation 441–444
alloimmune natural killer cells 484–485
alloimmune red blood cells (RBC) 32, 38
alloimmune skin substitutes 490, 490
allograft vasculopathy 405
alloimmune hematocoric disease 513
alloimmune thrombocytopenia 259–260, 259–260
alloantigens 259
immunogenetics and frequency of 259
passive alloimmune thrombocytopenia 263
severity of 259–260, 261
transplantation-associated alloimmune thrombocytopenia 263
see also neonatal alloimmune thrombocytopenia
alloimmunization
ABO blood group antigens 220
algorithm for platelet support management 225
blocking immune destruction of platelets 223–224
cancer 575–578
febrile, nonhemolytic transfusion reactions 653
HLA-selected platelet transfusions 221–222, 222
leukocyte-reduced blood components 281–282, 281–282
modified platelets and alternative hematostatic compounds 224
overcoming established alloimmunization 223–226
platelet antigens 217–226
platelet crossmatching 222–223
platelet selection 221–223
platelet-specific antigens 219–220
prevention of alloimmunity 224–225
Rh blood group system 181
suppression of immune response 224
thalassemia 137
therapeutic plasma exchange 400
transfusion monitoring 138–139
transfusion refractoriness 220–221, 241–243, 263–264
alpha–antitrypsin 287
alpha–proteinase inhibitor 312, 313
alphaviruses 594–595
ALT see alanine transferase
American Association of Tissue Banks (AATB) 464, 467–468, 473–474, 477–478
American Red Cross
adverse reactions after blood donation 43–47, 44
bacterial contamination of blood components 611–612
blood administration 25–26
donor recruitment and screening 30–31
historical overview 7
safety and availability of blood/blood products 69
American Society for Apheresis (ASFA) 379, 379–383, 393, 394–396, 396, 409–410, 417
American Society for Reproductive Immunology (ASRI) 697
America’s Blood Centers (ABC) 69
America’s Blood Centers/European Blood Alliance (ABC/EBA) 82
AML see acute myelogenous leukemia
anaphorbin C 664
anisoipoiosis 450
anaphylactic/anaphylactoid reactions 386
concepts and definitions 652, 658
diagnosis 659
etiology 658–659, 658
prevention 659–660
therapeutic plasma exchange 393
treatment 659
anaplastic large-cell lymphoma (ALCL) 451
ANC see absolute neutrophil count
anemia
adaptive mechanisms in 110–112, 111, 111
clinical outcomes 113–125
clinical settings of special interest 120–121
concepts and definitions 110
decision making in RBC transfusion 123–124
dose and administration in RBC transfusion 125
efficacy of transfusion 114–120, 115–119
erythrocytosis 93–95
future perspectives 125
hematocrit values 537–538
human studies 113–114
interaction between pathophysiologic processes and 112–113
iron deficiency 52, 94
microcirculatory effects of 112
perioperative transfusion needs 549–550, 555
preclinical laboratory studies 113
preoperative anemia management 15–17, 17
red blood cell transfusion 110–125
red blood cell transfusions for neonates and infants 535–538
risk factors 113–114, J13, 113
transfusion guidelines 121–123, 122
transfusion threshold 124–125
see also specific anemias
anemia of chronic inflammation (ACI) 95
anemia and RBC transfusion 124
perioperative transfusion needs 560
platelet transfusion 240
angiography 560
angiotensin-converting enzyme (ACE) inhibitors 393, 659, 663
ANH see acute normovolemic hemodilution
anonymity 60
antepartum maternal antibody screening 529–531
antepartum surveillance 531
antibiotics 353
antibodies
alloimmunization 224
carbohydrate blood groups 160, 160, 165
compatibility testing 200–201, 203
donor recruitment and screening 38
hematopoietic growth factors 427
hemolytic disease of the fetus and newborn 528–531, 529
hemolytic transfusion reactions 644–646, 646
immune-mediated thrombocytopenia 246–249
immunoglobulin products 360, 361
platelet transfusion 241–243
protein blood groups 185–186, 189
red cell antigen–antibody interactions 195–196
red cell immunology 195–196, 195–196
Rh blood group system 181, 184
therapeutic plasma exchange 397–398
transfusion-related acute lung injury 669, 678
anticoagulant–nutrient solutions 103–104
anticoagulation
apheresis 373
historical development 4–5, 6–7
paroxysmal nocturnal hemoglobinuria 156
perioperative transfusion needs 553–554
red blood cells 103–104
see also individual anticoagulants
antifibrinolytic agents 21, 334, 346–347
antigen-presenting cells (APC)
alloimmunization 219
leukocyte-reduced blood components 281–282
red cell immunology 193
transfusion-related immunomodulation 695
antigens
antigen receptors on T cells and B cells 193
autoimmune hemolytic anemias 145
carbohydrate blood groups 169–173
exposure to foreign protein antigens 193
hemolytic disease of the fetus and newborn 528–530, 529
human leukocyte antigen 458, 458, 461–462, 461
immunoglobulin products 360, 361
LW blood group system 183–184
malaria, blood groups, and hemoglobinopathy 127–128
platelet surface 215–217
platelet transfusion 241–243
protein blood groups 185–192
red cell antigen–antibody interactions 195–196
red cell immunology 193–196
Rh blood group system 179–183
thalassemia 136–137
therapeutic plasma exchange 400
transfusion-related acute lung injury 670–672
antiglobulin crossmatch 203
antihemophilic factor (AHF) 577
antihistamines 657–658
anti-idiotypic binding 365
antiphospholipid antibody syndrome (APS) 509
antiplatelet therapies 553–554
antiretroviral therapy (ART) 592
antithrombin 315
antithrombin III 314–315
APC see antigen-presenting cells
aPCC see activated prothrombin complex concentrate
apheresis
adverse reactions 48
anticoagulation 373
ASFA guidelines 379, 379–383, 382–383
bacterial contamination of blood components 614–615, 614
blood component separation 373
blood donor apheresis 374–375, 375
complications 385–386, 385–386
concepts and definitions 373–374, 374
donor apheresis instrumentation 375–376
donor recruitment and screening 36
donor vigilance and hemovigilance 66
frequency, duration, and discontinuation 385
leukocyte-reduced blood components 280
plasma 299, 374–376, 378, 383–385
platelet preparation 227, 228–229, 238
prescription 383
principles and technology of hemapheresis 373–387
product and procedure requirements 376–377
replacement fluids 384–385
uncategorized indications 382–383
vascular access 374
volume treated 383–384
see also therapeutic apheresis
aplastic anemia 401, 408
apoptosis 91–93, 92, 704
APS see antiphospholipid antibody syndrome
aPTT see activated partial thromboplastin time
ARDS see acute respiratory distress syndrome
argatroban 257
ART see antiretroviral therapy
arterial puncture 47
arteriovenous anastomosis 5–6, 5, 6
artificial antigen-presenting cells (aAPC) 483
artificial oxygen carriers 572–573
AS see additive solutions
ASFA see American Society for Apheresis
Ashwell–Morell receptor (AMR) 213
aspirin 237, 352–353
ASRI see American Society for Reproductive Immunology
Association for the Advancement of Medical Instrumentation (AAMI) 468–469
atherosclerosis 169
ATLS see Acute Trauma Life Support
ATP see adenosine triphosphate
atrial fibrillation (AF) 553
attribution theory 35
atypical hemolytic uremic syndrome (aHUS) 236, 508–509
autoantibodies
acquired bleeding disorders 351–352
autoimmune hemolytic anemias 148–149
immune-mediated thrombocytopenia 249
platelet transfusion 241–243
transfusion monitoring 138–140
transfusion-related immunomodulation 703–704
autoimmune disease 363, 367–368
autoimmune hemolytic anemia (AIHA) 1
44–153
AIHA due to warm IgM antibodies 151–152
classification 144, 145
clinical features 146, 146, 149, 151–152
cold agglutinin disease 144, 149–151
cold autoimmune hemolytic anemia 144, 149–151
diagnosis and differential diagnosis 146–147, 150–153
drug-induced immune hemolytic anemia 144, 152–153, 153
epidemiology and risk factors 144–145, 149, 151–152
hemolytic transfusion reactions 643, 646
paroxysmal cold hemoglobinuria 151
pathophysiology 145–146, 149, 151–152
prognosis 149, 151–153
therapeutic plasma exchange 401
transfusion management 148–153
treatment 147–148, 150–153
warm and cold, or mixed AIHA 152
warm autoimmune hemolytic anemia 144–149
autoimmune mucocutaneous bullous diseases 368
autologous donation 39–40, 39
autologous hematopoietic stem cell transplantation 440–441, 442
autologous natural killer cells 484
autologous skin substitutes 490
cardiovascular disease 113, 237
cardiopulmonary disease 132, 537
cardiopulmonary bypass 353
central nervous system (CNS) disorders 398
cardiac tissue
bioreactors 499
cell source 498–499
design goals for cardiac tissue regeneration 498
future directions 500
preclinical studies 499–500
scaffold 499
tissue banking 474–475
tissue engineering and regenerative medicine 498–500
cardiopulmonary bypass 353–354
cardiopulmonary disease 132, 537
cardiopulmonary bypass 353–354
cardiac allograft rejection 415
C/c antigens 178
Cartwright blood group system 191
CCI see Clinical Laboratory Improvement
Amendments
Centers for Medicare and Medicaid Services
Centers for Disease Control and Prevention
Center for International Blood and Marrow Transplant Research
cell salvage
celiac disease 463
cell salvage
indications and contraindications 19
patient blood management 18–19
sponge rinsing 19
succion 19
washed and unwashed cell salvage 18–19, 18
cellular transplantation 624
Center for International Blood and Marrow Transplant Research (CIBMTR) 444–445
Centers for Disease Control and Prevention (CDC) 409–410, 608
Centers for Medicare and Medicaid Services (CMS) 75, 77, 465–466
central nervous system (CNS) disorders 398
central venous catheter (CVC) 374
perioperative transfusion needs 558, 559
platelet transfusion 240
therapeutic plasma exchange 388–389, 392–393
cerebrovascular disease
anemia and RBC transfusion 112–113
secondary stroke prevention 131
sickle cell anemia 130–131
stroke prevention 130–131
therapeutic apheresis 408–409
transfusion therapy 131
CFR see Code of Federal Regulations
CFU see colony-forming units
CFU-E see colony-forming units-erythroid
CFU-GM see colony-forming units-granulocyte macrophage
CFU-MK see colony-forming units-megakaryocyte
cGMp see current good manufacturing practices
Chagas disease 602–603
CHD see coronary heart disease
catelact therapy
chelating agents 690–691, 691
compliance 692
initiation of chelation 691–692, 692
intensification of chelation 693, 693
iron overload 690–694, 694
monitoring 693–694, 693
transfusion monitoring 140–141
chemiluminescent immunoassays (ChLIA) 626–627
chemotherapy-induced neutropenia 424–425
chemotherapy-induced thrombocytopenia 428
Chido/Rodgers blood group system 190
Chikungunya virus (CHIKV) 594–595
children see pediatric patients
chimeric antigen receptors (CAR) 482
ChLIA see chemiluminescent immunoassays
chlorambucil 150
CHMP see Committee for Medicinal Products for Human Use
cholera 165
cholinesterase inhibitors 397–398
chromatographic pathogen reduction 639
chromatographic procedures 305–306, 306
chromium-51 labeling 108–109
chronic anemia 124
chronic idiopathic demyelinating polyneuropathy (CIDP) 367–368, 397
chronic lymphocytic leukemia (CLL) 450
chronic maternal anemia 510
chronic myelogenous leukemia (CML) 267, 445, 450
chronic regional pain syndrome type 2 (CRPS II) 2, 47
chronic renal failure 421–422
CIBMTR see Center for International Blood and Marrow Transplant Research
CIDP see chronic idiopathic demyelinating polyneuropathy
circulating steel factor (SLF) 432–433
citrant anticoagulants
adverse reactions 48, 660–661, 665
apheresis 373, 385–386
therapeutic plasma exchange 391–392
citrate–phosphate–dextrose (CPD) 103–104, 227
citrate–phosphate–dextrose–adenine–1 (CPDA-1) 338, 661
CJD see Creutzfeldt–Jakob disease
ClairTg process 309
CLIA see Clinical Laboratory Improvement Amendments
clinodamycin and quinine (CQ) 602
clinical decision support software (CDSS) 14–15
Clinical Laboratory Improvement Amendments (CLIA) 74–77
clinical trials
anemia and RBC transfusion 114–125,
115–119
gene therapy 454–455
immunomodulation 283
perioperative transfusion needs 350–554
safety and availability of blood/blood products 81
sickle cell anemia 131–132
tissue engineering and regenerative medicine 501–502, 501
transfusion-related immunomodulation 704, 705, 708–709
CLI see chronic lymphocytic leukemia
clonal selection 194
clotidoprogel 353
Clostridium spp. 467, 612, 616
clotting
fibrinolysis 294
historical development 7
plasma 287–288
termination of 290
see also coagulation
clotting protein disorders 338–343
combined factor V and factor VIII deficiency 339–340
factor V deficiency 339
factor X deficiency 340
factor XI deficiency 340–341
factor XII deficiency 341–342
fibrinogen disorders 342–343
prothrombin deficiency 338–339
clustered regularly interspaced short palindromic repeats (CRISPR) 453–454
CML see chronic myelogenous leukemia
CMS see Centers for Medicare and Medicaid Services
CMV see cytomegalovirus
CMS see central nervous system coagulation
carbohydrate blood groups 165
classical model of coagulation cascade 292
inhibition of, and termination of clotting 290
initiation and amplification of 290
plasma 289–290, 289–290, 291
screening tests 292–294, 293
thrombin generation, fibrin clot formation and stabilization 290
see also clotting
coaulation factor concentrates
acquired bleeding disorders 344–357
acquired factor X deficiency 352
acquired von Willebrand syndrome 351–352
antifibrinolytic agents 346–347
anti thrombotic therapy 354–357
cardiopulmonary bypass 353–354
clinical settings 347–357
compatibility testing
Committee for Medicinal Products for Human
Code of Federal Regulations (CFR) 70
cobblestone area-forming cell (CAFC) assay 431
cobalamin deficiency 399
coagulopathy 399
colony-forming units-erythroid (CFU-E) 88, 430
colony-forming units (CFU) 430
combined factor V and factor VIII
Cohn process 303
cold autoimmune hemolytic anemia 149
coagulopathy 399
coagulation factor inhibitors
acquired bleeding disorders 350
plasma 287–288
therapeutic plasma exchange 401–402
coagulopathy 399
cobalamin deficiency 93–94
cobblestone area-forming cell (CAFC) assay 431
Code of Federal Regulations (CFR) 70–75
CoE see Council of Europe
Coga, Arthur 2
Cohn process 303–304, 304
cold agglutinin disease (CAD) 144, 146, 149–151, 401
cold autoimmune hemolytic anemia 149–151
College of American Pathologists (CAP) 74–75, 77, 611
colony-forming units (CFU) 430
colony-forming units-erythroid (CFU-E) 88, 91–92, 520
colony-forming units-granulocyte macrophage
(CFU-GM) 518
colony-forming units-megakaryocyte
(CFU-MK) 522–523, 523
Colton blood group system 190
combined factor V and factor VIII deficiency 339–340
commitment, model of 35
Committee for Medicinal Products for Human Use (CHMP) 81–82
compatibility testing
ABO typing 199, 200
automated pretransfusion testing 201
biovigilance 204
blood administration 204
crossmatch 203–204
DNA-based typing 202–205, 205
donor testing 198–199
donor–recipient testing 203–204
elements of pretransfusion testing 198
emergency release 204
historical development 6
issue 204
labeling 204
patient testing 199–201
principles of antibody identification 201–202, 202
reagent red cells for antibody screening 201
red blood cells 193, 198–205
Rh typing 200
selection of blood for transfusion 203
tests for unexpected antibodies 200–201, 201, 203
compensatory anti-inflammatory response syndrome (CARS) 700–701
complementarity-determining regions (CDR) 194
complement scaving 365–366
complete blood cell count (CBC) 245, 516
computerized physician order entry (CPOE) 14–15
confirmatory tests 155–156, 628
genital aplastic anemia 685–686
genital dyserythropoietic anemia (CDA) 685–686
genital hemolytic anemias 141–143, 142
genital neutropenias 268, 270
genital nonspherocytic hemolytic anemia 142
genital platelet disorders 236
connective tissue 472–473
consent 435
conservative transfusion 554–555
corneal tissue 502–504
coronary artery bypass graft (CABG) 346–347
coronary heart disease (CHD) 54
corrected count increment (CCI) 221, 241
corticosteroids 147, 250
Council of Europe (CoE) 62, 81
CPD see citrate–phosphate–dextrose
CPDA-1 see citrate–phosphate–dextrose–adenine-1
CPOE see computerized physician order entry
CPSI see Canadian Patient Safety Institute
CQ see clindamycin and quinine
Creutzfeldt-Jakob disease (CJD)
clinical transmissibility by blood and tissue 621–622
donor recruitment and screening 622–624
historical overview 620
nature, concentration, and distribution of infectivity 621
pathogen reduction technology 639–640
prevalence and distribution of subclinical infection 622
tissue banking 473
transfusion and transplantation 624–625
CRISPR see clustered regularly interspaced short palindromic repeats critically ill patients 675
Crohn’s disease 697
Cromer blood group system 191
crossmatch
alloimmunization 222–223
compatibility testing 203–204
platelet transfusion 243
CRPS II see chronic regional pain syndrome type II
cryoglobulinemia 402
cryoprecipitate
bacterial contamination of blood components 609
blood administration 24
clotting protein disorders 342–343
hemophilia 330
pathogen reduction technology 635
plasma transfusions for infants and children 547–548, 547
von Willebrand disease 338
cryopreservation
hematopoietic stem cell transplantation 441
plasma 288–289
plasma and cryoprecipitate for transfusion 295–301
platelets 233–234
red blood cells 107
tissue banking 471, 474
umbilical cord blood stem cells 437
CTCL see cutaneous T-cell lymphoma
CTL see cytotoxic T-cells
current good manufacturing practices (cGMP)
70–72, 71, 74–75
cutaneous T-cell lymphoma (CTCL) 414–415
CVC see central venous catheter
cyclophosphamide 148, 242, 443–444
cyclosporine 148, 252
cytomegalovirus (CMV) 137, 448–449
adoptive immunotherapy 479–480, 484
cancer 579
leukocyte-reduced blood components 283–284
obstetric transfusion practice 512
platelet transfusions for infants and children 545
red blood cell transfusions for neonates and infants 539–540
testing for pathogens in donors 630–631
transfusion-transmitted virus infections 595
ctyotic T-cells (CTL) 479–480
ctyotic therapy 148, 150
DAH see diffuse alveolar hemorrhage
damage control resuscitation 556–558, 568
danaparoid sodium 257–258
danazol 148, 252
D antigen 177, 178, 181–183, 199
darbepoetin alfa 421
DAT see direct antiglobulin test
DBA see Diamond–Blackfan anemia
DBM see demineralized bone matrix
DC see dendritic cell
DCM see dilated cardiomyopathy
DDAVP see desmopressin
DEA see diethyleneamine
deep vein thrombosis (DVT) 17, 256, 258–259
defective products 76
deferasirox (DFX) 141, 691–692, 691
deferiprone (DFP) 141, 690–692, 691
deferoxamine B mesylate (DFO) 141, 690, 691, 692
DEHP see di(2-ethylhexyl)phthalate
delayed hemolytic transfusion reaction (DHTR) 140, 642, 650
delayed serologic transfusion reaction (DSTR) 642
ECMO see extracorporeal membrane oxygenation
ECO see enzyme-converted group O
ECP see extracorporeal photochemotherapy
ecizumab 156–157
EDQM see European Directorate for the Quality of Medicines
EEA see European Economic Area
EIA see enzyme immunoassay
electrocardiography (ECG) 660–661
electrolyte disorders 661, 665
ERFE see erythroferrone
erythroid growth factors 418
erythrocytapheresis 138, 410
eryptosis 102
see ERFE
eculizumab 156
enzyme-linked immunosorbent assay (ELISA) 222
enzyme immunoassay (EIA) 651
enzyprin alfa 420–421, 420
epsilin aminocaproic acid (EACA) 21
Epstein–Barr virus (EBV) 480–481, 595
epitfbatide 255
ERFE see erythroferrone
erythropoiesis 102
erythrophagocytosis 647
erythropoiesis 87–90
anemia of chronic inflammation 95
cellular events in erythroid differentiation 88
erthroxophoitin in the fetus and neonate 520
extracellular requirements for erythroid differentiation 89–90
fetal and neonatal hematopoiesis 520–521
fetal erythroid progenitors 520
fotol or cobalamin deficiency and macrocytic anemia 93–94
hematopoietic stem cells 87
hemoglobins 520–521, 522
intracellular requirements for normal erythroid differentiation 89
iron deficiency and microcytic anemia 94
iron overload 686
nutritional requirements 93–95
physiological hemolysis after birth 520, 521
stages of 87–89
thalassemia, ineffective erythropoiesis, and microcytosis 94–95
erthropoietin (EPO) 90–93
effects on erythroid progenitor cells 91
erthrocyte production kinetics 91–93, 92
fetal and neonatal hematopoiesis 520
hematopoietic growth factors 420–421
proeoperative anemia management 16–17
red blood cell transfusions for neonates and infants 535–536
regulation of EPO production by tissue hypoxia 90, 90–91
erthropoietin-stimulating agents (ESA) 575–576
Escherichia coli 175
euthanol 638–639
EUAHS see European Hemophilia Safety Surveillance
European Commission 80
European Committee on Blood Transfusion (CD–PS–TS) 81–82
European Directorate for the Quality of Medicines (EDQM) 81–82
European Economic Area (EEA) 80
European Hemophilia Safety Surveillance (EUHASS) 82
European Medicines Agency (EMA) 80–82
European Pharmacopoeia (EP/Ph Eur) 81, 310–311
European Union (EU) 80–81
evidence-based transfusion guidelines 14
exchange transfusion 323, 324–334, 547
exchange volume 389–390, 389–390
EXM see electronic crossmatch
Expert Committee on Biological Standardization (ECBS) 79
extracorporeal membrane oxygenation (ECMO) 543, 547
eextracorporeal photochemotherapy (ECP) cardiac and lung allograft rejection 415
cutaneous T-cell lymphoma 414–415
graft-versus-host disease 415–416
specialized therapeutic plasma processing 416
therapeutic apheresis 414–416, 414
eextracorporeal photopheresis 379
extraembryonic tissue 476
extravascular hemolysis 145–146
ex utero collection 436
exo vivo-engineered DC vaccines 483
factor V 339–340
factor V inhibitors 352
factor VIIa 21–22, 326
factor VIII 312
clotting protein disorders 339–340
dosage and administration 331–333, 332
gene therapy 454
plasma 311, 312, 317, 318–319, 319
recombinant blood products 321–324, 330–331, 331
transfusion-related immunomodulation 703
factor VIII inhibitor bypass activity (FEIBA) 344–345, 357
factor VIII inhibitors 350–351, 350
factor IX dosage and administration 333
gene therapy 454
plasma 317
recombinant blood products 324–326, 325, 333, 333
factor X 311–312, 340, 352
factor Xa 349
factor Xa inhibitors 293, 554
factor XI 312–313, 340–341
factor XIII 341–342, 347
familial hypercholesterolemia (FH) 405, 417
fascia lata 473
Fas ligand 91, 704
FAST see focused ultrasonographic survey for trauma
fetal familial insomnina 620
FBS see fetal blood sampling
FCR see fraction of cells remaining
FcRn see neonatal Fc receptor
FDA see Food and Drug Administration
FDC see follicular dendritic cells
FDCA see Food, Drug, and Cosmetic Act
FDP see fibrin degradation products
febrile, nonhemolytic transfusion reactions (FNHTR) 652–657
alloimmunization to leukocytes or platelets 653
bacterial contamination of blood components 654
concepts and definitions 652, 665
diagnosis 654–655
etiology 652–653, 654
leukocyte-reduced blood components 282–283
platelet storage 232–233
prevention 656–657
storage-generated cytokines 653–654
treatment 655–656
FEIBA see factor VIII inhibitor bypass activity
FEP see free erythrocyte protoporphyrin
ferritins 50, 52–55, 56, 140–141
fetal and neonatal hematopoiesis 516–527
erthropoiesis 520–521
fetal erythroid progenitors 520
granulocyteopoiesis 516–520
hematopoietic growth factors 517
hemoglobin 520–521, 522
megakaryocyte progenitors 522–523, 523
megakaryocytes 523, 524
neonatal neutropenia 518–520
neonatal thrombocytopenia 527
physiological hemolysis after birth 520, 521
regulation of neutrophil production 517–518
sites of fetal neutrophil production 516–517, 518–519
thrombopoiesis 522–527
thrombopoietin and TPO mimetics 524–527, 525–526
fetal blood sampling (FBS) 513
fetal or neonatal alloimmune thrombocytopenia (FNATT) 216–217, 219, 514
fetal typing 180–181
FFP see fresh frozen plasma
FGS see focal glomerulosclerosis
FH see familial hypercholesterolemia
fractionation 303–304, 304
fraction of cells remaining (FCR) 384, 407
free erythrocyte protoporphyrin (FEP) 51
frequent plasmapheresis 66
fresh frozen plasma (FFP) 24, 26
clothing protein disorders 342–343
cryoprecipitate for transfusion 295
donor recruitment and screening 37
pathogen reduction technology 632–635
transfusion for infants and children 547
therapeutic plasma exchange 390–391
transfusion-related acute lung injury 677–678
trauma and burns 566, 571
frozen bone 471
frozen plasma (FP) 295–301
FUT1 gene 162–163, 163
FUT2 gene 167–168, 168
FUT3 gene 167
G6PD see glucose-6-phosphate dehydrogenase
galeciens 171
Gamunex process 308
gastrointestinal disease 133
gata-1 gene 187
GBGT1 gene 174
GBS see Guillian-Barré syndrome
GCNT2 gene 169–171
G-CSF see granulocyte colony-stimulating factor
gel column testing 200–201, 201
gene expression 432
gene-modified T-cell receptors 481–482
gene therapy 452–455
administration 452, 452
clinical trials 454–455
concepts and definitions 452
vector selection 453, 453
virus inactivation 453
genotoxicity 453
genotyping
autoimmune hemolytic anemias 148–149
compatibility testing 199–200
human leukocyte antigen 459–463
immune-mediated thrombocytopenia 248–249
Rh blood group system 180–181
Gerlich blood group system 127, 190
Gerstmann-Sträusler-Scheinker (GSS)
disease 620–621
gestational thrombocytopenia 508–509
GIL blood group system 190
global coagulopathy 546
glucose-6-phosphate dehydrogenase (G6PD)
deficiency 128, 141–142, 142, 351, 646
glucose metabolism 97–100
Emden–Meyerhof pathway 97–98, 99
pentose shunt 99–100
platelets 230
Rapaport–Luebering shunt 99, 100, 100
glycophorins A and B 185, 186
glycoprotein Iib/IIia antagonists 255
glycoproteins
alloimmunization 219
drug-induced platelet dysfunction 353
hematopoietic stem cells 431–432, 432
immune-mediated thrombocytopenia 246, 259–260, 260
Kell and XK blood group systems 187, 190
platelets 229
Rh blood group system 181–182
therapeutic plasma exchange 397–401
glycosphingolipids (GSL) 172–175, 172
glycosylphosphatidylinositol (GPI) 153, 155–156, 191–192, 191
GM-CSF see granulocyte macrophage colony-stimulating factor
Goodpasture syndrome (GPS) 403, 405
GPI see glycosylphosphatidylinositol
GPS see Goodpasture syndrome
Grading of Recommendations Assessment, Development and Evaluation (GRADE) 14, 16
graft failure see rejection
graft-versus-host disease (GVHD)
adoptive immunotherapy 481, 484–485
extracorporeal photopherochemistry 415–416
grading and staging 446
hematopoietic stem cells 433–435
hematopoietic stem cell transplantation 440–443, 446–449
neutrophils 274
pathogen reduction technology 633
see also transfusion-associated graft-versus-host disease
graft-versus-tumor (GVT) effect 440
granulocyte colony-stimulating factor
(G-CSF) 49, 265, 269–270, 418
adverse reactions 664
cancer 578
cellular use of 424–425
donor vigilance and hemovigilance 66
effects and adverse effects 424
fetal and neonatal hematopoiesis 518
hematopoietic stem cells 432–433
neutrophils 271–277, 274–275
structure, function, and physiology 422–423
granulocyte macrophage colony-stimulating factor (GM-CSF)
265, 423–424, 432–433, 518
granulocytes
apheresis 376
blood administration 24
collection 49
granulocyte transfections (GTX)
adverse reactions 664
assessment of modern granulocyte transfusion 273–276
cancer 578
historical overview 272–273, 273
neutrophils 271–272
pediatric GTX 276
prophylactic granulocyte transfections 271, 273, 275–276
recommendations for clinical practice 276–277
therapeutic GTX 272–275
inflammatory disease 363, 367–368
influenza viruses 397
informed consent 36
infusion flow rates 27–28, 656
inherited bleeding disorders
 clotting protein disorders 338–343
hemophilia 328–335
obstetric transfusion practice 509–510
von Willebrand disease 335–338
inmate immunity 165
insertional mutagenesis 453
inspections 72
integrins 430
integument 134
intensive care units (ICU)
anemia and RBC transfusion 121
fetal and neonatal hematopoiesis 516
plasma 296, 298
platelet transfusions for infants and children 542–543
transfusion-related immunomodulation 702
trauma 569
INTERCEPT System 633–634, 635
interdonation interval 48–49, 54
interferon (IFN) 480–481
interleukins (IL) 265, 428
adoptive immunotherapy 485
febrile, nonhemolytic transfusion reactions 653
hemolytic transfusion reactions 647–648
International Conference on Harmonization of Technical Requirements (ICH) 81–82
International Hemovigilance Network (IHN) 59, 62
International Plasma Fractionation Association (IPFA) 82
International Quality Plasma Program (IQPP) 40
International Society for Blood Transfusion (ISBT) 30, 62, 67, 82, 163
International Society on Thrombosis and Hemostasis (ISTH) 82
International Working Group on the Standardization of Genomic Amplification Techniques (SoGAT) 82
intracranial hemorrhage (ICH) 346
Intragram process 310
intravascular hemolysis 145–146, 644
intravenous immunoglobulin (IVIG) 148
alloimmunization 223–224
dosing and scheduling IgG treatment regimens 366–368
hemolytic disease of the fetus and newborn 528, 533–534
hemolytic transfusion reactions 649
history of commercial IgG production 361–362
hyperimmune globulins 369
IgG in transplantation 368–369
immune-mediated thrombocytopenia 250–254, 251, 262–263
indirect, non-competitive actions 366
mechanisms of action of IVIG 359, 365–366
pharmacokinetics and metabolism of IgG 362–363
plasma 287
intravenous Rh immune globulin (RhIg) 251, 253–254
in utero collection 436
inverse TRALI 672, 678
in vivo–engineered DC vaccines 483
in vivo recovery 108–109
ion exchange chromatography 305
IPD see individual-patient-data
IPFA see International Plasma Fractionation Association
IQPP see International Quality Plasma Program
iron deficiency adverse effects 53–54
blood donation 49–56
concepts and definitions 49–50
erythroid growth factors 422
ferritin testing 54–55
measurement of iron status in blood donors 53
increased interdonation interval 54
iron absorption in blood donors 50
iron supplementation 55–56, 55
measurement of iron status 50–52, 50
microrythia anemia 94
mitigation of 54–56
prevalence and risk factors in blood donors 52–53
iron-deficiency anemia (IDA) 52
iron-deficient erythropoiesis (IDE) 52–53
iron overload 685–694
chelation therapy 690–694, 694
clinical features 688
concepts and definitions 685
management 690–694
measurement of iron burden 688–689
pathophysiology 685–687, 686
therapeutic apheresis 409
transfusional iron burden 687–688
transfusion monitoring 140–141
iron supplementation 55–56, 55
irradiation
blood administration 26
cancer 575, 577
red blood cells 106, 540
ISBT see International Society for Blood Transfusion
isolated heparin-induced thrombocytopenia 258–259
ISTH see International Society on Thrombosis and Hemostasis
ITI see immune tolerance induction
ITP see idiopathic thrombocytopenic purpura;
immune thrombocytopenic purpura
IVIG see intravenous immunoglobulin
Ixodes scapularis 410
JMH blood group system 191
Joint Commission 76–77
JF blood group system 192
Kawasaki syndrome 367
Kell blood group system 187–188, 188
Kidd blood group system 189, 189
kidney see renal
King, Edmund 2
KIOVIG process 308
Knops blood group system 127, 191
laboratory studies
autoimmune hemolytic anemias 146, 150–152
hematopoietic stem cells 431
paroxysmal nocturnal hemoglobinuria 155
transfusion-related acute lung injury 675–676
see also individual tests
lactate dehydrogenase (LDH) 646
LAK see lymphokine-activated killer
Lambert–Eaton myasthenic syndrome (LEMS) 397–398
LAN blood group system 192
Landsteiner, Karl 5–6
large granular lymphocytes (LGL) 268
LCMV see lympatic choriomeningitis
LCT see lymphocytotoxicity
LDH see lactate dehydrogenase
LDL see low density lipoprotein
leishmaniasis 604–605
Leishmania spp. 604–605
LEMS see Lambert–Eaton myasthenic syndrome
lentiviruses 590–593
leuparin 257
leukapheresis see granulocyte collection
leukocytapheresis 378, 413–414
leukocyte-reduced blood components 278–285
apheresis 280
bacterial overgrowth 284
blood administration 25–26, 25
centrifugation 279
clinical indication 281–282
cost-effectiveness 284–285
febrile, nonhemolytic transfusion reactions 282–283, 656
filtration 279–280, 279
HLA immunization 281–282, 281–282
immunomodulation 283–284
preparation 227–228
prestorage, poststorage, and bedside 280
process control 280
red blood cells 106
red cell and platelet storage 278–279
red eye syndrome 663
secondary alloimmunization 282
techniques for leukocyte removal 279–280
transfusion-associated graft-versus-host disease 283
transfusion-related acute lung injury 284
transmission of CMV infection 283–284
leukocytes 653–654, 656, 676
leukocytosis 267
leukoerythroblastosis 267
Lewis blood group 165–169
biological roles 168–169
blood transfusion and transplantation 168
Lewis gene 167
malaria, blood groups, and hemoglobinopathy 127–128
molecular biology 167–168, 168
secretor gene 167–168, 168
serology 166, 166
synthesis and biochemistry 166–167, 166
LGL see large granular lymphocytes
liberal transfusion 554–555
LIC see liver iron concentration ligament 472
limbic encephalitis 398
lipopolysaccharides (LPS) 617
lipotechoic acid (LTA) 617
liver see hepatic
liver iron concentration (LIC) 689, 693–694
LKE see Lake antigen on erythrocytes
LMW see low-molecular-weight
long-term culture initiating cell (LTC-IC) assay 431
low density lipoprotein (LDL) cholesterol 405, 417
Lower, Richard 1–2
low-molecular-weight heparins 355–356
low-molecular-weight (LMW) dextran IV iron preparations 16–17
LP see lumbar puncture
LPS see lipopolysaccharides
LTA see lipotechoic acid
LTC-IC see long-term culture initiating cell
Lake antigen on erythrocytes (LKE) 172–173
lumbar puncture (LP) 240, 560
lung allograft rejection 415
lung biopsy 559–560
lung injury 447
see also transfusion-related acute lung injury
lupus anticoagulants 351
Lutheran blood group system 187, 187
LW blood group system 183–184
basis for antigen expression 183–184
biological roles 184
genes and their expressed proteins 183
history and nomenclature 183
lymphatic choriomeningitis (LCMV) 597
lymphocytotoxicity (LCT) assay 222–223
lymphokine-activated killer (LAK) cell therapy 484
lymphoma 444, 450–451
lyophilized bone 464, 471–472
lyophilized platelets 234
mAb see monoclonal antibodies
MAC see membrane attack complex
macrocystic anemia 93–94
macrothrombocytopenia 211–212
magnetic biosusceptometry 689
magnetic resonance imaging (MRI) 688–689, 692
MAHA see microangiopathic hemolytic anemia
MAIPA see monoclonal antibody immobilization of platelet antigen
major histocompatibility complex (MHC)
adaptive immunotherapy 484
alloimmunization 219
disease association 463
genes and pseudogenes 456–457, 457
hematopoietic stem cell transplantation 441
historical overview 456, 457
leukocyte-reduced blood components 281–282
malaria
blood groups and hemoglobinopathy 126–129, 127, 165
detection and screening 604
epidemiology 603–604
obstetric transfusion practice 512–513
therapeutic apheresis 409–410
transfusion transmission of 603–604
malignancy see cancer
Mansonia spp. 606
mantle cell lymphoma 451
manual exchange transfusion 138
MAPK see mitogen-activated protein kinase
Marburg virus 596
narrow stromal cells 430, 431
massive and rapid transfusion 660–663
citrate toxicity 660–661
concepts and definitions 660
electrolyte disorders 661
hypothermia 661–662
microaggregate debris 662
plasma 298
transfusion-associated circulatory overload 652, 662–663, 662
massive bleeding 557
massive fetomaternal hemorrhage 515
maternal antibody screening 529–531
maternal mortality ratio (MMR) 507
maternal thrombocytopenia 508–509, 509
May–Hegglin anomaly 212
MB see methylene blue
MCH see mean cell hemoglobin
M-CSF see monocyte/macrophage colony stimulating factor
MCV see mean corpuscular volume
MDS see myelodysplasia syndrome
mean cell hemoglobin (MCH) 521, 522
mean corpuscular volume (MCV) 521, 522
mean platelet volume (MPV) 245, 253
medical devices 73
megakaryocyte progenitors 522–523, 523
megakaryocytes 426, 523, 524
megakaryocytic-erythroid progenitor (MEP) 87–88
megakaryopoiesis
control of megakaryopoiesis 207–210
differentiation of megakaryocytes 210
genetic regulation 208–210
platelet feedback model of 213
proliferation of megakaryocytes 206–207, 207
spike model of TPO regulation 208, 209
thrombopoietin 206, 208, 209
MEHP see mono(2-ethylhexyl)phthalate
membrane attack complex (MAC) 146, 149
membrane metabolism 101
membrane mutation 128
meniscus 472
MEP see megakaryocytic-erythroid progenitor
mesenchymal stromal cell (MSC)
immunotherapy 485–487, 486
clinical applications 486
future directions 486–487
meta-analysis 121, 123
metabolic alkalosis 386
methylene blue (MB)-light treatment 633
MG see myasthenia gravis
MHC see major histocompatibility complex
microaggregate debris 662
microalbuminuria 133
microangiopathic hemolytic anemia
(MAHA) 236–237
microchimerism 707–708
microcytic anemia 94
microcytosis 94–95
microfilariasis 606
milk transfusion 5
Mirasol System 634–635
mitogen-activated protein kinase (MAPK) 208
mixed autoimmune hemolytic anemia 152
MMN see multifocal motor neuropathy
MMR see maternal mortality ratio
MNS blood group system 127, 185–186, 186
MODS see multiple-organ dysfunction syndrome
MOF see multiple-organ failure
mono(2-ethylhexyl)phthalate (MEHP) 663
monoclonal antibodies (mAb) 148, 431–432
monoclonal antibody immobilization of platelet antigen (MAIPA) assay 219, 223, 246, 247
monoclonal gammopathy 397
monoclonal proteins 399
monocyte/macrophage colony-stimulating factor (M-CSF) 418, 518
monocytes 670
MP see multipot testing
MPN see myeloproliferative disorders
MPV see mean platelet volume
MRI see magnetic resonance imaging
MS see multiple sclerosis
MSC see mesenchymal stromal cell
multicomponent collections 377
multifocal motor neuropathy (MMN) 368
multiple-hit/threshold theory 672–673, 673
multiple myeloma 444, 450
multiple-organ dysfunction syndrome (MODS) 700
multiple-organ failure (MOF) 699–700, 700
multiple sclerosis (MS) 398–399
multipot testing (MP) 627–628, 635–637
myasthenia gravis (MG) 397
mycoplaxe 252
myeloid growth factors 422–425
clinically available products 423–424
clinical use of 424–425, 424
effects and adverse effects 424, 424
implications for transfusion medicine 425
structure, function, and physiology 422–423
myelopoesis 265
myeloproliferative disorders (MPN) 445, 449–450
myelosuppression 445–446
NADP/NADPH see nicotinamide adenine dinucleotide phosphate
NAIT see neonatal alloimmune thrombocytopenia
narcolepsy 462–463
NAT see nucleic acid testing; nucleic amplification technique
National Blood Service (UK) 30–31
national competent authorities (NCA) 81
National Donor Deferral Registry (NDDR) 40
National Institute of Biological Standards and Control (NIBSC) 82
natural killer (NK) cell immunotherapy 483–485
activating receptors and cytokines 484
adaptive NK cells 484
allogeneic NK cells 484–485
autologous NK cells 484
donor NK cell products 485
future directions and preclinical strategies 485
NK cell biology, tolerance, education and learning 483–484
natural killer (NK) cell lymphoma 451
natural killer (NK) cells 269
NCA see national competent authorities
NDDR see National Donor Deferral Registry
necrotizing enterocolitis 169
neonatal alloimmune thrombocytopenia (NAIT) 238, 260–262
neonatal treatment 261
platelet-antibody assays 247
prenatal management 261–262
neonatal alloimmune thrombocytopenic purpura (NAITP) 542–543
neonatal Fc receptor (FcRn) 321
neonatal neutropenia 518
NET see neutrophil extracellular traps
NETosis 266
neuromyotonia 398
neurosurgery 560
neutropenia 267–270
neutrophilia 266
neutrophil extracellular traps (NET) 669
neutrophilia 266–267, 267
neutrophils 265–270
assessment of modern granulocyte transfusion 273–276
clearance 266
collection for transfusion 271–272
donor marrow stimulation 271–272
fetal and neonatal hematopoiesis 516–520, 518–519
historical overview 272–273, 273
hydroxethyl starch 272
migration into tissues 266
mobilization of 265–266
NETosis 266
neutropenia 267–270, 425
neutrophilia 266–267, 267
normal neutrophil kinetics 265–266
pediatric GTX 276
production in marrow 265
prophylactic granulocyte transfusions 271, 273
recommendations for clinical practice 276–277
therapeutic GTX 272–275
transfusion in clinical medicine 272–276
transfusion-related acute lung injury 669–670, 672
next-generation sequencing 460
NIBSC see National Institute of Biological Standards and Control
nicotinamide adenine dinucleotide phosphate (NADP/NADPH) 99–101
NICU see neonatal intensive care units
nitrile oxide (NO) 644, 658
NK see natural killer
nonhydrostatic pulmonary edema 675–676
non-steroidal anti-inflammatory drugs (NSAID) 237, 352–353
non-transferrin-bound iron (NTBI) 687, 689
non-transfusion-dependent-thalassemia (NTDT) phenotype 136, 138
nonvolemic anemia 111–113
NOR phenotype 173
NSAID see non-steroidal anti-inflammatory drugs
NTBI see non-transferrin-bound iron
NTDT see non-transfusion-dependent-thalassemia
nucleic acid testing (NAT) bacterial contamination of blood components 617
donor management and reentry testing 628, 629
pathogen reduction technology 632–633, 640
testing for pathogens in donors 627–629
tissue banking 466, 468
nucleic amplification technique (NAT) 585–587
OBRR see Office of Blood Research and Review
observed studies 114
obstetric transfusion practice 507–515
alloimmune hemolytic disease 513
assessment of blood loss 510, 511
blood loss in pregnancy 507–510
blood products and precautions 512–513
chronic maternal anemia 510
donor blood, volume, and rate of transfusion 513
fetal or neonatal alloimmune thrombocytopenia 514
fetal transfusions 513–515
gestational thrombocytopenia, ITP, and HELLP 508–509
hematological causes of blood loss 507–508
indications 510–512
inherited bleeding disorders 509–510
major obstetric bleeding 510–511
maternal thrombocytopenia 508–509, 509
maternal transfusions 510–513
obstetrical causes of blood loss 507
outcome of treatment 513–514
platelet transfusions 512
postpartum anemia 511–512
technique 513
TPP and HUS 509
Octagam process 307
octanoic acid 638
ocular tissue
cell sources 503
clinical applications 503–504
objectives of tissue-engineered cornea 502–503
scaffold 503
tissue banking 473–474
tissue engineering and regenerative medicine 502–504
Office of Blood Research and Review (OBRR) 74
Official Medicines Control Laboratory (OMCL) 81
OK blood group system 192
OMCL see Official Medicines Control Laboratory
oncology patient see cancer
ophthalmologic complications 131
organ procurement organizations (OPO) 464–466
orthochromatic erythroblasts (OrthoEB) 88–89
osteomyelitis 133–134
Ottenberg, Reuben 6
oxygen delivery
anemia and RBC transfusion 112–113, 124
perioperative transfusion needs 551
platelets 231
red blood cells 97, 98, 107–108
PIPK synthase 173–174
PAF see platelet-activating factor
pain 134–135
PANDAS see pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection
pandemic influenza 597
para-Bombay phenotype 161
paracentesis 559
paraneoplastic neurologic syndromes 398
parasite transmission during transfusion 599–607
babesia 599–602
Chagas disease 602–603
leishmaniasis 604–605
malaria 603–604
microfilariasis 606
toxoplasmosis 605–606
parathyroid tissue 475
paroxysmal cold hemoglobinuria 146, 151
paroxysmal nocturnal hemoglobinuria (PNH) 153–157
classification 144, 153
clinical features 154–155
clinical settings of special interest 157
diagnosis and differential diagnosis 155–156
epidemiology and risk factors 153–154
pathophysiology 154
pediatric patients 157
prognosis 157
transfusion management 157
treatment 156–157
partial thromboplastin time (PTT) 566
parvovirus B19 175, 515, 595–596
PAS see platelet additive solutions
passive alloimmune thrombocytopenia (PAT) 263
Pasteur effect 230
pasteurization 637–638
PAT see passive alloimmune thrombocytopenia
pathogen inactivation (PI) 632, 635–639
pathogen reduction technology (PRT) 632–641
blood products 632–637, 633
manufacturing controls and final product safety assessment 640
pooled plasma, S/D treated 636–637
prions 636, 639–640
red blood cells 107
single-donor plasma and platelets 633–635
small-pool S/D treatment and filtration 635
virus inactivation and removal 636–639, 639–640
patient blood management (PBM) 13–22
acute normovolemic hemodilution 19–20
plasticity 432
plasticizer toxicity 663–664
platelet-activating factor (PAF) 658, 658
platelet activation assays 247
platelet additive solutions (PAS) 232–233, 233
platelet-antibody assays 246, 247, 248
platelet function disorders 352
plateletpheresis 228–229
platelet-rich plasma (PRP) 227
platelet-rich platelets (PRP) 238
platelets
ABO blood group antigens 215–216, 216, 220
acquired bleeding disorders 352–354
active bleeding 344
adverse reactions 47–49
alloimunization 217–226
alternative sources 229
antibodies on platelet surface 215–217
apheresis 375, 377, 412–413
apheresis-derived 227, 228–229
bacterial contamination of blood components 610–615, 610
blood administration 24
buffy coat method 228
cancer 576–577
component modification 233
crossmatching 217–218
donor recruitment and screening 37, 39
early megakaryopoiesis 206–207, 207
effective, nonhemolytic transfusion reactions 653–654
genotyping 248–249
hemolytic transfusion reactions 644–645
hemophilia 334
HLA antigens 215–216, 217–219, 218, 221–222
HLA-selected platelet transfusions 221–222, 222
insights into production and sizing 211–212
kinetics 212–214
late megakaryopoiesis 210
leukocyte-reduced blood components 278–279
lifespan and its regulation 212–214
metabolic fuel availability 230–231, 230
molecular and cellular physiology 233–234
novel storage techniques 212–214
obstetric transfusion practice 512
overcoming established alloimmunization 223–226
pathogen reduction technology 632–635
pathophysiologic basis of thrombocytopenia 543–544
pathophysiology of thrombocytopenia in infants 542–543
perioperative transfusion needs 558
physical MK changes 210–211
platelet feedback model of megakaryopoiesis 213
platelet products and administration 238
platelet-specific antigens 216–217, 217, 219–220
platelet storage lesion 231–232
platelet substitutes 243
platelet transfusion thresholds 543–545, 543–544
preparation 227–229, 228
pre-procedure platelet transfusions 240
product selection for infants and children 545
prophylactic platelet transfusion 239–240, 544–545
respiratory capacity 231
storage container composition 231
storage preparation 227
storage temperature and metabolism 229–230, 229
therapeutic platelet transfusions 240–241
thrombopoietin receptor agonists 243
transfusion reactions 545–546
transfusion-related acute lung injury 670
transfusions for infants and children 542–546
trauma 565
turnover rate and survival in the circulation 212
von Willebrand disease 337
whole blood-derived 227–228
see also immune-mediated thrombocytopenia
see also thrombocytopenia
PMCA see protein folding cyclic amplification
PMN see polymorphonuclear
Pneumocystis carinii (PCP) 448
PNH see paroxysmal nocturnal hemoglobinuria
point-of-care testing 20
POISE-2 trial 554
poisoning 405
polycythemia vera 409, 410–411
polyethylene glycol (PEG) 638–639, 650
polymeerase chain reaction (PCR)
bacterial contamination of blood components 617
human leukocyte antigen 460
immune-mediated thrombocytopenia 248–249
parasite transmission during transfusion 602, 604, 606
testing for pathogens in donors 627–628
polymorphonuclear (PMN) leukocytes 257, 271–277
polyomoviruses 403
postdonation information (PDI) 64
postpartum anemia 511–512
postpartum hemorrhage (PPH) 507, 511
posttransfusion infection 283
pretransfusion purpura (PTP) 237–238
alloimmunization 216, 219
pathogenesis 262
therapeutic plasma exchange 400–401
rehabilitation 262–263
PPH see postpartum hemorrhage
PPR see percent platelet recovery
PPTA see Plasma Protein Therapeutics Association
PRAC see Pharmacovigilance Risk Assessment Committee
precipitation 638–639
preclinical laboratory studies 113
pregnancy
blood loss in pregnancy 507–510
fetal transfusions 513–515
immune-mediated thrombocytopenia 253
maternal transfusions 510–513
obstetric transfusion practice 507–515
paroxysmal nocturnal hemoglobinuria 157
sickle cell anemia 135
see also hemolytic disease of the fetus and newborn
prekallikrein activator (PKA) 310
premedication 656, 658
preoperative anemia algorithm for detection, evaluation, and management 17
hematopoietic growth factors 422
patient blood management 15–17
preterm infants, red blood cell transfusions 353–356
pretransplantation blood transfusion 283
priapism 133, 408
primary thrombocytosis 412–413, 413
priapism diseases 620–625
approaches to risk management 622
blood component processing 624
cellular, tissue, and organ transplantation 624
clinical transmissibility of CJD by blood and tissue 621–622
donor screening assays 623–624
donor selection 622–623
epidemiology 620
ethical, legal, and societal considerations 624–625
historical overview 620
molecular basis 621
nature, concentration, and distribution of infectivity 621
pathogen reduction technology 636, 639–640
plasma derivative manufacture 624
prevalence and distribution of subclinical infection 622
Privigen process 309
product deviations 72–73, 72, 76
PROMMTT study 567–568
PROPPR study 568–569, 568
prostaglandin E2 (PGE2) 653, 656
protein assays 626–630, 627
protein blood groups 185–192, 186
antigens on glycosylphosphatidylinositol-linked proteins 191–192, 191
Chido/Rodgers blood group system 190
Colton and GIL blood group systems 190
Diego blood group system 186, 189–190
Duffy blood group system 188–189, 189
Gerich blood group system 190
Indian blood group system 191
Kell and XK blood group systems 187–188, 188
Kidd blood group system 189, 189
Knops blood group system 191
Lutheran blood group system 187, 187
LW blood group system 183–184
minor blood group systems 192
MNS blood group system 185–186, 186
Rh blood group system 179–183
Scianna blood group system 190
Xg blood group system 190
protein folding cyclic amplification (PMCA) 623
protein-specific platelet-antibody assays 246
prothrombin complex concentrates (PCC) 316–317, 316
acquired bleeding disorders 344–345, 345
blood administration 24–25
patient blood management 21
perioperative transfusion needs 554
trauma and burns 571–572
prothrombin deficiency 338–339
prothrombin time (PT) 293–294, 293, 299–300, 566
PRP see platelet-rich plasma
PRT see pathogen reduction technology
 Psorales-italiolet light treatment (PUVA) 633–634
Psuedomonas spp. 609, 616
P synthase 174
PT see prothrombin time
Pseudomonas 609, 616
Public Health Service Act (PHSA) 70–71
pulmonary edema 675–676
pulmonary hypertension 132
pulmonary microvasculature 669, 670
pure red cell aplasia 401
PUVA see psoralen-ultraviolet light treatment
pyrimidine 5’ nucleotidase deficiency 531
pyruvate kinase deficiency (PKD) 142, 531
quality assurance (QA)
red blood cells 108–109
safety and availability of blood/blood products 71–72, 72, 74–75, 79
quality control (QC) 74, 437
RA see rheumatoid arthritis
radiology 675
Rapaport–Luebering shunt 99, 100, 100
RAPH blood group system 192
rapid immunoassay 617
rapid infusion practices 28
rapidly progressive glomerulonephritis (RPGN) 403–404
RBC see red blood cells
real-time polymerase chain reaction 249
reasoned action, theory of 35
rebound thrombocytopenia 427
receiver operating characteristics (ROC) curve 52
recombinant blood products
blood administration 24–25
cancer 578
fetal and neonatal hematopoiesis 525–527, 525–526
patient blood management 21–22
recombinant HVI 572
recombinant FIX 324–326, 325, 333, 333
recombinant FVIIIa 21–22, 326, 345–346, 346, 567, 578
recombinant FVIII 321–324, 330–331, 331
recombinant FXIII 342
safety and availability of blood/blood products 81–82
trauma and burns 567, 572
von Willebrand disease 338
von Willebrand factor as rate-limiting factor 324
recruitment see donor recruitment and screening
recurrent spontaneous abortions (RSA) 697
red blood cells (RBC)
adaptive mechanisms in anemia 110–112, 111
additive solutions 103–106, 105, 538–539, 539
adverse reactions 47–48
alloimmunization 218
alternative substrates for red cell metabolism 100
anemia and RBC transfusion 110–112
anemia of chronic inflammation 95
anticoagulant–nutrient solutions 103–104
apheresis 374–375, 377
autoimmune hemolytic anemias 144, 145–146
bacterial contamination of blood components 608–609, 609
blood administration 23–28
blood banks 540
cancer 574–576, 575
cellular events in erythroid differentiation 88
clinical outcomes of anemia 113–123
clinical settings of special interest 120–121, 122, 123
collection and separation procedures 103
compatibility testing 193, 198–205
cytomegalovirus-safe RBC units 539–540
decision making 123–124
donor recruitment and screening 32, 37–39
and administration 125
effects of erythropoietin on erythroid progenitor cells 91
efficacy of transfusion 114–120, 115–119
erythropoiesis 102
erythrocyte production kinetics 91–93, 92
erythropoiesis 87–90, 93–95
erythropoietin 90–93, 90–92
extracellular requirements for erythroid differentiation 89–90
factors influencing RBC quality 106–107
folate or cobalamin deficiency and macrocytic anemia 93–94
fresh versus stored units 538–539, 538
frozen storage 107
future perspectives 125
glucose metabolism 97–100
hematocrit values 536–538
hemolytic disease of the fetus and newborn 531
hemolytic transfusion reactions 648–651
historical development 9, 10
history of RBC storage systems 102–103
immunology 193–198
interaction between pathophysiologic processes and anemia 112–113
intracellular requirements for normal erythroid differentiation 89
iron deficiency 51–52, 94
irradiation 106, 540
leukocyte-reduced blood components 106, 278–280
liquid preservation 102–107, 104
massive and rapid transfusion 660–661
membrane metabolism 101–102
metabolism 97–102
microcirculatory effects of anemia 112
microcytic anemia 94
nutritional requirements for erythropoiesis 93–95
obstetric transfusion practice 512
oxygen delivery 97, 98, 107–108
paroxysmal nocturnal hemoglobinuria 144
pathogen reduction 107
pathogen reduction technology 632, 635
pathophysiology of anemia of prematurity 535–536
patient blood management 15
perioperative transfusion needs 549–552, 554–556
preservation in transfusion medicine 97, 98, 102–107
production and kinetics 87–96
protein blood groups 185
RBC salvage devices 28
regulation of energy metabolism 100–101
regulation of EPO production by tissue hypoxia 90, 90–91
renovation 107
Rh blood group system 182
risk factors for anemia 113–114, 113, 113
sickle cell anemia 132
storage container composition 106
synthetic processes 101
temperature and time lapses 106, 106
thalassemia 136–137, 138
thalassemia, ineffective erythropoiesis, and microcytosis 94–95
therapeutic apheresis 407–408
transfusion guidelines 121–123, 122
transfusion practices 536–538
transfusion-related immunomodulation 695–704, 707–708
transfusions for neonates and infants 535–541
transfusion threshold 124–125
trauma 563–564
validation of RBC quality and in vivo recovery 108–109
washing 106
red cell enzynopathies 141–142, 531
red cell membrane disorders 142–143, 531
red eye syndrome 663
reduced-intensity conditioning regimens 444, 444, 445
reentry testing 628, 629
refractory alloimmunization 220–221, 241–243
Refsum’s disease 405
regenerative medicine see tissue engineering and regenerative medicine
regulatory T cells 482
rejection 404, 415, 446
rejuvenation 107
renal allografts 695–697
renal biopsy 240
renal disease 133, 644
renal failure 399, 421–422
repetitive phlebotomy 22
replacement fluids 384–385, 390–391, 390, 393
replication-competent viruses 453
reporting and learning systems (RLS) 58
reporting systems
defective products 76
product deviations 72–73, 72, 76
transfusion service errors 75–76
reproductive tissue 475–476
respiratory disease 131–132
respiratory dysfunction 675–676
restless leg syndrome (RLS) 53
restriction fragment length polymorphism (RFLP) 248
resuscitation 556–558, 568, 570–573
reticulated platelets (RP) 207, 211, 213
reticuline fibrosis 427
retinopathy 131
Retrovirus Epidemiology Donor Study 36
retroviruses 590
RFLP see restriction fragment length polymorphism
Rh blood group system 179–183
altered CE 179–180, 180
autoimmune hemolytic anemias 148–149
basis for antigen expression 177
biological roles 181–182
cancer 576
C/c and E/e antigens 178–180
compatibility testing 198–200, 202–204
D antigen 177–178, 179, 181–183
donor recruitment and screening 38
endored 178
genes and their expressed proteins 177–181, 178
hemolytic disease of the fetus and newborn 528–529
history and nomenclature 176, 177
immune response 182–183
partial 181
partial D 178
RH genotyping 180–181
Rh membrane complex 181
Rhnull phenotype 181
serology 182–183
weak 181
weak D 177–178
RHCE gene 177–181
RHD gene 177–181
rheumatoid arthritis (RA) 402
Rhlg see intravenous Rh immune globulin
ribonulin-light treatment 634–635
RISE study 52–53
rituximab 148, 150, 251–252
RLS see reporting and learning systems; restless leg syndrome
ROC see receiver operating characteristics
romiplostim 426
rotational thromboelastometry (ROTEM) 553–554, 557
ROTEM see rotational thromboelastometry
Rous–Turner solution 102
RP see reticulated platelets
RPGN see rapidly progressive glomerulonephritis
RSA see recurrent spontaneous abortions
SAA see severe aplastic anemia
safety and availability of blood/blood products 69–83
AABB Standards 69, 74, 76
blood collection establishments 70–74
blood establishment computer software 73
College of American Pathologists 74–75, 77
concepts and definitions 69
defective product reporting 76
device regulatory controls 73
European perspective 80–83, 80
Food and Drug Administration 70–76, 82–83
historical development 8–9
history of US drugs and biologics
regulation 69–70
hospital transfusion services 74–78
inspections 72
international perspective 78–80
Joint Commission 76–77
plasma derivative and recombinant blood products 81–82
promotion of blood component safety 82–83
reporting of product deviations 72–73, 72, 76
Transfusion Medicine Committee 77–78
transfusion service errors 75–76, 78
United States perspective 69–78
World Health Organization 69, 78–80
SAG-M see saline–adenine–glucose–mannitol
SAL see Sterility Assurance Level
saline–adenine–glucose–mannitol (SAG-M)
solution 103–104
sargramostim 424
SARS-CoV, carbohydrate blood groups 165
SAPS see subcutaneous immunoglobulin
SAX see saline–adenine–glucose–mannitol
S/D see saline–adenine–glucose–mannitol
sepsis 475–476
serotonin release assay (SRA) 247
severe anemia 134
severe aplastic anemia (SAA) 685–686
severe cardiopulmonary disease 537
severe chronic neutropenia 425
severe congenital neutropenias (SCN) 268, 270
Shigella dysenteriae 175
SHOT reports 63, 67–68
sickle cell anemia
cardiopulmonary disease 132
cerebrovascular disease 130–131
clinical review of transfusion indications 129–135, 135
gastrointestinal disease 133
hematologic disease 134
immune dysfunction and sepsis 132–133
integument 134
ophthalmologic complications 131
pain 134–135
phenotype and genotype distributions 126
phytophytic model 129, 130
pregnancy 135
prevalence 126
renal disease 133
respiratory disease 131–132
skeletal disorders 133–134
structural hemoglobin mutations 128–129
surgical patients 134
transfusion monitoring 138–141
sickle cell disease (SCD)
gene therapy 454–455
hemolytic disease of the fetus and newborn 530–531
iron overload 685–687, 689
life- or organ-threatening complications 408–409
primary and secondary prevention of stroke 408–409
therapeutic apheresis 408–409
transfusional iron overload 409
sickle cell HTR syndrome 643–644
simple transfusion 137–138
SIRS see systemic inflammatory response syndrome
skeletal disorders 133–134
skin
acral cell skin substitutes 489–490
alloimmune skin substitutes 490, 490
autologous skin substitutes 490
design goals for skin substitutes 489
structure and function 489
tissue banking 473
tissue engineering and regenerative medicine 489–490
skin preparation 613
skin ulcers 134
SLE see systemic lupus erythematosus
SLF see circulating steel factor
SoGAT see International Working Group on the Standardization of Genomic Amplification Techniques
solid-organ transplantation
carbohydrate blood groups 164
immune-mediated thrombocytopenia 263
transfusion-related immunomodulation (TRIM) (Continued)
studies before-and-after WBC reduction 701–702
Transfusion Requirements in Critical Care (TRICC) trial 114
Transfusion Safety Office (TSO) 13–14
transfusion service errors 75–76, 78
transfusion threshold 124–125
transfusion-transmitted infections (TTI)
donor recruitment and screening 33
pathogen reduction technology 632
syphilis 609–610
transplantation-associated alloimmune transient abnormal myelopoiesis (TAM) 542
transplant-related mortality (TRM) 442
TT virus (TTV) 597
TTTS
TTP
TSOAC
see TSO
TSO
see TSE
TSE
see TSI
Treponema pallidum
transfusion service errors 75–76, 78
trauma 562
trauma-associated coagulopathy 565–566
trauma-associated coagulopathy 565–566
Treponema pallidum 609–610, 630
TRICC trial 114, 123
TRM see transplant-related mortality
Trypanosoma cruzi 602–603
tissue 481
TSE see Transfusion Safety Office
TSS see target-specific oral anticoagulants
TT see thrombin time
TTI see transfusion-transmitted infections
TTP see thrombotic thrombocytopenic purpura
TTTS see twin-to-twin transfusion syndrome
TTV see transfusion-transmitted virus infections
TT virus (TTV) 597

transfusion-related immunomodulation (TRIM)
(Continued)
studies before-and-after WBC reduction 701–702
Transfusion Requirements in Critical Care (TRICC) trial 114
Transfusion Safety Office (TSO) 13–14
transfusion service errors 75–76, 78
transfusion threshold 124–125
transfusion-transmitted infections (TTI)
donor recruitment and screening 33
pathogen reduction technology 632
syphilis 609–610
testing for pathogens in donors 629–631
transfusion-transmitted virus infections (TTVI) 583–598
alphaviruses 594–595
Filoviridae 596–597
flaviruses 593–594
hepatitis virus infections 583–590
herpesviruses 595
lentiviruses 590–593
lymphatic choriomenigitis 597
pandemic influenza 597
parvovirus B19 595–596
retroviruses 590
TTF virus 597
transient abnormal myelopoiesis (TAM) 542
transmissible spongiform encephalopathies (TSE) see prion diseases
transplantation-associated alloimmune thrombocytopenia 263
transplant-related mortality (TRM) 442–443
TRAP study 218, 221, 226, 282
trauma 562–573
adjuncts in transfusion therapy 571–573
burns 570–573
clinical approach to the mass casualty trauma situation 569
clinical approach to the trauma patient 568–569
damage control resuscitation 556–558, 568
epidemiology of physical injury 564–568, 564
historical overview 562–564
initial resuscitation of burns patient 570
massive and rapid transfusion 660
plasma 298
transfusion-related immunomodulation 700–701
transfusion therapy for the severely burned 570–571
trauma-associated coagulopathy 565–566
trauma-associated coagulopathy 565–566
Treponema pallidum 609–610, 630
TRICC trial 114, 123
TRM see transplant-related mortality
Trypanosoma cruzi 602–603
TSE see prion diseases
TSO see Transfusion Safety Office
TSS see target-specific oral anticoagulants
TT see thrombin time
TTI see transfusion-transmitted infections
TTP see thrombotic thrombocytopenic purpura
TTTS see twin-to-twin transfusion syndrome
TTV see transfusion-transmitted virus infections
TT virus (TTV) 597

transfusion-related immunomodulation (TRIM)
(Continued)
studies before-and-after WBC reduction 701–702
Transfusion Requirements in Critical Care (TRICC) trial 114
Transfusion Safety Office (TSO) 13–14
transfusion service errors 75–76, 78
transfusion threshold 124–125
transfusion-transmitted infections (TTI)
donor recruitment and screening 33
pathogen reduction technology 632
syphilis 609–610
testing for pathogens in donors 629–631
transfusion-transmitted virus infections (TTVI) 583–598
alphaviruses 594–595
Filoviridae 596–597
flaviruses 593–594
hepatitis virus infections 583–590
herpesviruses 595
lentiviruses 590–593
lymphatic choriomenigitis 597
pandemic influenza 597
parvovirus B19 595–596
retroviruses 590
TTF virus 597
transient abnormal myelopoiesis (TAM) 542
transmissible spongiform encephalopathies (TSE) see prion diseases
transplantation-associated alloimmune thrombocytopenia 263
transplant-related mortality (TRM) 442–443
TRAP study 218, 221, 226, 282
trauma 562–573
adjuncts in transfusion therapy 571–573
burns 570–573
clinical approach to the mass casualty trauma situation 569
clinical approach to the trauma patient 568–569
damage control resuscitation 556–558, 568
epidemiology of physical injury 564–568, 564
historical overview 562–564
initial resuscitation of burns patient 570
massive and rapid transfusion 660
plasma 298
transfusion-related immunomodulation 700–701
transfusion therapy for the severely burned 570–571
trauma-associated coagulopathy 565–566
trauma-associated coagulopathy 565–566
Treponema pallidum 609–610, 630
TRICC trial 114, 123
TRM see transplant-related mortality
Trypanosoma cruzi 602–603
TSE see prion diseases
TSO see Transfusion Safety Office
TSS see target-specific oral anticoagulants
TT see thrombin time
TTI see transfusion-transmitted infections
TTP see thrombotic thrombocytopenic purpura
TTTS see twin-to-twin transfusion syndrome
TTV see transfusion-transmitted virus infections
TT virus (TTV) 597
tumor necrosis factor (TNF) 647–648, 653
twin anemia–polycythemia sequence (TAPS) 515
twin-to-twin transfusion syndrome (TTTS) 515
TXA see tranexamic acid
UBC see umbilical cord blood
UDHQ see Uniform Donor History Questionnaire
ULR see universal leukocyte reduction
tularemia 342
UVT see ultraviolet
UV see ultraviolet
vaccination
adoptive immunotherapy 483
hemophilia 334
transfusion-transmitted virus infections 586–587
vapor heat treatment 638
variant Creutzfeldt–Jakob disease (vCJD) see variant Creutzfeldt–Jakob disease
VEGF see vascular endothelial growth factor
VIE see vascular endothelial growth factor
VIEL blood group system 192
venipuncture 23, 66
veno-occlusive disease (VOD) 443–444, 447
vinca alkaloids 252
VIPS S/D–F 635
virus inactivation and removal 304–305, 636–639, 639–640
visible-light treatment 633, 634–635
vitamin K deficiency 293–294, 340, 348, 354–357
VOD see veno-occlusive disease
volume reduction 26, 577
von Willebrand disease (vWD) see von Willebrand disease
von Willebrand factor (vWF) see von Willebrand factor
warfarin
acquired bleeding disorders 354–355, 355
plasma 299
reversal of warfarin effect 299
thrombocytopenia 256
warm and cold autoimmune hemolytic anemia 152
warm autoimmune hemolytic anemia 144–149
clinical features 146
diagnosis and differential diagnosis 146–147
epidemiology and risk factors 144–145
pathophysiology 145–146
prognosis 149
transfusion management 148–149
treatment 147–148
WAS see Wiskott–Aldrich syndrome
warming
blood administration 26
red blood cells 106
umbilical cord blood stem cells 437–438
washed cell salvage 18–19, 18
WBD see whole blood-derived
Western blotting 246
West Nile virus (WNV) 466–467, 594, 630, 631
WHF see World Federation of Hemophilia
whole blood (WB) see whole blood
adverse reactions 47
donor recruitment and screening 37
leukocyte-reduced blood components 278–285
leukocytosis 267
neutrophil collection and transfusion 271–277
neutrophil production and kinetics 265–270
platelet preparation 227
therapeutic apheresis 413–414
transfusion-related immunomodulation 695–697, 699–708
WHO see World Health Organization
whole blood assays 20
whole blood collection
adverse reactions 43–44, 44, 47–48
apheresis 374
donor recruitment and screening 37
donor vigilance and hemovigilance 66
whole blood-derived (WBD) platelets 227–228, 614–615
Wiskott–Aldrich syndrome (WAS) 212, 455
WNV see West Nile virus
World Federation of Hemophilia (WFH) 82
World Health Organization (WHO)
access to safe blood transfusion 78–79
advisory groups 79–80
donor recruitment and screening 32–33
donor vigilance and hemovigilance 58, 62
historical development 9
preoperative anemia management 15–16
prion diseases 621
quality assurance and safety programs 79
safety and availability of blood/blood products 69, 78–80
transfusion safety 78
transfusion-transmitted virus infections 590
wrong blood in tube (WBIT) 644–645
Wuchereria bancrofti 606
Xg blood group system 190
XK blood group system 187–188, 188
Yersinia enterocolitica 608–609
zinc finger nuclease (ZFN) 453–454
zinc protoporphyrin (ZnPP) 51
zygosity testing 180